Alpha-Emitting Radionuclides: Current Status and Future Perspectives
Pharmaceuticals · 08.01.2024 · 17 (1) · 76
DOI: 10.3390/ph17010076 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 08.01.2024. Verfasst von Matthias Miederer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Imaging in Oncology, National Center for Tumor Diseases (NCT/UCC), 01307 Dresden, Germany. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The use of radionuclides for targeted endoradiotherapy is a rapidly growing field in oncology. In particular, the focus on the biological effects of different radiation qualities is an important factor in understanding and implementing new therapies. Together with the combined approach of imaging and therapy, therapeutic nuclear medicine has recently made great progress. A particular area of research is the use of alpha-emitting radionuclides, which have unique physical properties associated with outstanding advantages, e.g., for single tumor cell targeting. Here, recent results and open questions regarding the production of alpha-emitting isotopes as well as their chemical combination with carrier molecules and clinical experience from compassionate use reports and clinical trials are discussed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Translational Imaging in Oncology, National Center for Tumor Diseases (NCT/UCC), 01307 Dresden, Germany.
- Medizinische Fakultät and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
- Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 01328 Dresden, Germany.
- Research Group Molecular Biology of Systemic Radiotherapy, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstr, 400, 01328 Dresden, Germany.
ORCID-Profile: Matthias Miederer, Constantin Mamat, Marc Pretze, Klaus Kopka
Förderung
- NCI NIH HHS
Zitieren
APA
Miederer, M., Benešová-Schäfer, M., Mamat, C., Kästner, D., Pretze, M., Michler, E., Brogsitter, C., Kotzerke, J., Kopka, K., Scheinberg, D. A., & McDevitt, M. R. (2024). Alpha-Emitting Radionuclides: Current Status and Future Perspectives. Pharmaceuticals, 17(1), 76. https://doi.org/10.3390/ph17010076
Vancouver
Miederer M, Benešová-Schäfer M, Mamat C, Kästner D, Pretze M, Michler E, et al. Alpha-Emitting Radionuclides: Current Status and Future Perspectives. Pharmaceuticals. 2024;17(1):76. doi:10.3390/ph17010076
BibTeX
@article{Miederer2024,
author = {Miederer, Matthias and Benešová-Schäfer, Martina and Mamat, Constantin and Kästner, David and Pretze, Marc and Michler, Enrico and Brogsitter, Claudia and Kotzerke, Jörg and Kopka, Klaus and Scheinberg, David A and McDevitt, Michael R},
title = {Alpha-Emitting Radionuclides: Current Status and Future Perspectives},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {1},
pages = {76},
doi = {10.3390/ph17010076}
}
EUVIMED